| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 58.7 | 57.0 | 49.9 |
| Other income | 1.9 | 1.4 | 1.0 |
| Total income | 60.6 | 58.4 | 50.9 |
| Profit before exceptional items & tax | -0.2 | 4.3 | 6.5 |
| Profit before tax | -0.2 | 4.3 | 6.5 |
| Net profit | -0.2 | 3.2 | 4.8 |
| Operating margin | -0.3% | 7.4% | 12.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +17.60% |
|---|---|
| Operating profit, year on year | -138.20% |
| Operating profit, quarter on quarter | -172.40% |
NSE results filing, NSE: MADHAVBAUG. Figures extracted from the filing.
Vaidya Sane Ayurved Laboratories Ltd: key numbers
- Share price
- ₹135.95
- Market cap
- ₹142.9 Cr
- Revenue (annual)
- ₹106.9 Cr
- Net profit (annual)
- ₹8.99 Cr
- P/E (TTM)
- 15.9×Sector 34.9×
- Promoter holding
- 66.34%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaidya Sane Ayurved Laboratories Ltd
All →Vaidya Sane Ayurved Laboratories Other Announcement
The Company has filed an undertaking confirming that Corporate Governance provisions under Regulation 27 of SEBI (LODR) are not applicable for the current quarter.
Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories held its 27th AGM on September 30, 2026. Shareholders considered the adoption of financial results, auditor re-appointments, and approval of ESOP 2026.
Vaidya Sane Ayurved Laboratories Annual General Meeting
Vaidya Sane Ayurved Laboratories will hold its 27th Annual General Meeting on September 30, 2026, via video conferencing. The company also filed its FY 2025-26 Annual Report.
Vaidya Sane Ayurved Laboratories Board Meeting Outcome
The company's board approved the 27th AGM details, director/auditor re-appointments, an increase in MD remuneration, and the introduction of the 'VSALL - ESOP 2026' scheme.
Vaidya Sane Ayurved Laboratories Other Announcement
Vaidya Sane Ayurved Laboratories filed a statement of deviation or variation in fund utilization pursuant to Regulation 32(1) for the quarter ended June 30, 2026.
Vaidya Sane Ayurved Laboratories Management Change
Vaidya Sane Ayurved Laboratories announced the resignation of Rohit Madhav Sane as CEO. Mr. D. Ramakrishna has been appointed as the new CEO and KMP.